These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34939897)

  • 21. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
    Hildesheim A; Wacholder S; Catteau G; Struyf F; Dubin G; Herrero R;
    Vaccine; 2014 Sep; 32(39):5087-97. PubMed ID: 25018097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
    Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
    Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
    Szarewski A; Poppe WA; Skinner SR; Wheeler CM; Paavonen J; Naud P; Salmeron J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Hedrick J; Jaisamrarn U; Limson G; Garland S; Romanowski B; Aoki FY; Schwarz TF; Bosch FX; Harper DM; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Int J Cancer; 2012 Jul; 131(1):106-16. PubMed ID: 21858807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.
    Hu S; Xu X; Zhu F; Hong Y; Hu Y; Zhang X; Pan Q; Zhang W; Zhang C; Yang X; Yu J; Zhu J; Zhu Y; Chen F; Zhao S; Karkada N; Tang H; Bi D; Struyf F; Zhao F
    Hum Vaccin Immunother; 2021 Apr; 17(4):955-964. PubMed ID: 33180670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.
    Sierra MS; Tsang SH; Hu S; Porras C; Herrero R; Kreimer AR; Schussler J; Boland J; Wagner S; Cortes B; Rodríguez AC; Quint W; van Doorn LJ; Schiffman M; Sampson JN; Hildesheim A;
    J Infect Dis; 2021 Aug; 224(3):503-516. PubMed ID: 33326576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
    Harper DM
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: A 10-year follow-up study.
    Zhao F; Jastorff A; Hong Y; Hu S; Chen W; Xu X; Zhu Y; Zhu J; Zhang X; Zhang W; Xu D; Wang D; Tang R; Sun Y; Shen Y; Pan Q; Yin J; Liu D; Liu B; Karkada N; Jiang C; Cui J; Chen F; Bi J; Bao Y; Zhou X; Cartier C; Hu Y; Borys D
    Asia Pac J Clin Oncol; 2023 Aug; 19(4):458-467. PubMed ID: 36101936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
    Tota JE; Struyf F; Hildesheim A; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Lehtinen M; Wheeler CM; Sampson JN
    J Infect Dis; 2021 May; 223(9):1576-1581. PubMed ID: 32887990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
    Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
    Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
    Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
    Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K; Romanowski B
    BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
    ; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
    Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions.
    Ma M; Zhu J; Yang Y; Wang X; Jin Y; Zhang J; Wu S
    Cancer Med; 2022 Mar; 11(6):1542-1552. PubMed ID: 34981653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial.
    Konno R; Tamura S; Dobbelaere K; Yoshikawa H
    Int J Gynecol Cancer; 2010 Apr; 20(3):404-10. PubMed ID: 20375805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
    Wheeler CM; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; James M; Vuocolo S; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):936-44. PubMed ID: 19236277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
    Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
    BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.